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Background: The acceptability of female-controlled biomedical prevention technologies has not been established
in Papua New Guinea, the only country in the Pacific region experiencing a generalised, moderate-prevalence HIV
epidemic. Socio-cultural factors likely to impact on future product uptake and effectiveness, such as women’s ability
to negotiate safer sexual choices, and intravaginal hygiene and menstrual practices (IVP), remain unclear in this
setting.
Methods: A mixed-method qualitative study was conducted among women and men attending a sexual health
clinic in Port Moresby. During in-depth interviews, participants used copies of a hand-drawn template to indicate
how they wash/clean the vulva and/or vagina. Interviewers pre-filled commercially available vaginal applicators with
2-3mL KY JellyW to create a surrogate vaginal microbicide product, which was demonstrated to study participants.
Results: A total of 28 IDIs were conducted (women=16; men=12). A diverse range of IVP were reported. The
majority of women described washing the vulva only with soap and water as part of their daily routine; in
preparation for sex; and following sexual intercourse. Several women described cleaning inside the vagina using
fingers and soap at these same times. Others reported cleaning inside the vagina using a hose connected to a tap;
using vaginal inserts, such as crushed garlic; customary menstrual ‘steaming’ practices; and the use of material
fragments, cloth and newspaper to absorb menstrual blood. Unprotected sex during menstruation was common.
The majority of both women and men said that they would use a vaginal microbicide gel for HIV/STI protection,
should a safe and effective product become available. Microbicide use was considered most appropriate in
‘high-risk’ situations, such as sex with non-regular, transactional or commercial partners. Most women felt confident
that they would be able to negotiate vaginal microbicide use with male sexual partners but if necessary would be
prepared to use product covertly.
Conclusions: Notional acceptability of a vaginal microbicide gel for HIV/STI prevention was high among both
women and men. IVP were diverse in nature, socio-cultural dimensions and motivators. These factors are likely to
impact on the future acceptability and uptake of vaginal microbicides and other biomedical HIV prevention
technologies in this setting.
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Women bear a disproportionate burden of HIV, consti-
tuting over 50% of all those living with HIV worldwide
and nearly 60% in sub-Saharan Africa [1]. In many coun-
tries, gender inequity means that women are unable to
negotiate condom use, especially within marriage. Safe,
effective, affordable HIV prevention methods that are
initiated and controlled by women have therefore been
seen as a high priority for HIV prevention. Vaginal
microbicides are gels, cream or other topical prepara-
tions applied by a woman to reduce her risk of acquiring
HIV sexually [2]. Some preparations have been designed
for application immediately before and/or after each va-
ginal sex act (e.g. gels, dispersible tablets, films), whilst
others such as intravaginal rings are intended to be
placed in the vagina and to release microbicide over sev-
eral weeks, providing protection independent of the tim-
ing of sexual activity. The past two decades have seen a
number of trials of candidate microbicides, but until re-
cently, none had been proven to be safe and effective in
clinical trials [3-5]. A major breakthrough occurred in
2010 when the CAPRISA 004 trial in South Africa found
that vaginally-administered tenofovir gel reduced HIV
acquisition in women by 39% overall (and by 54% in
those with high adherence), and was safe, acceptable and
well tolerated [6]. Furthermore, the gel provided a simi-
lar level of protection to women against acquisition of
Herpes simplex type-2 (HSV-2). Should these results
be confirmed in a second trial [7], a new era in HIV
prevention can truly begin.
The availability of a new prevention technology how-
ever, raises new questions for public health policy makers.
In order for tenofovir gel and other tenofovir-based
microbicides currently in development (such as vaginal
films and dispersible pessaries [8-10]) to have the greatest
impact, research is required to understand the diverse
socio-cultural, behavioural and structural contexts into
which such products could be introduced [11]. Informa-
tion is also required on their acceptability to women and
their sexual partners, and the impact that vaginal microbi-
cide use may have on other HIV prevention strategies,
particularly condom acceptability and use [11-14]. For ex-
ample, research in Africa showed that although vaginal
microbicides were conceived as female controlled meth-
ods that could be used covertly and not require male con-
sent, in practice most women inform their partners,
showing that acceptability and use need to be seen in the
context of couple relationships [13]. The same research
further showed how cultural preference for specific sexual
practices interacted with microbicide acceptability [15]. A
study among female sex workers (FSWs) in Uganda [16]
found that foaming microbicide tablets and sponges were
the most popular delivery mechanisms, and gel and film
the least. Participants found the gel too messy and worriedthat the film would not dissolve. They liked the sponges
because they could insert them in the morning and would
be prepared for unexpected sex. Alternatively, in the
MDP301 trial [4], married women in the same area of
Uganda were very positive about study gel because it
enhanced sexual enjoyment due to increased lubrication.
It is possible that these differences were related to the dif-
ferent kinds of sexual relationships that the women in the
two studies had and/or to the different physical properties
of the two gels. This suggests that different products will
be preferred in different contexts, and that acceptability
research is necessary in different potential target groups.
Intravaginal hygiene and menstrual practices (IVP)
have been recognised as possible risk factors for HIV and
STI acquisition in women [17-23] and important influ-
ences on the acceptability and efficacy of vaginal micro-
bicides in HIV prevention trials [24-28]. Research from a
variety of developed and developing countries indicates
that IVP are common among women at different levels
of HIV/STI acquisition risk [15,17,24,27-35]. For ex-
ample, in a study among women working in food and
recreational facilities in Mwanza, Tanzania, Allen et al.
(2010) found that intravaginal cleansing using fingers,
water and soap was considered necessary to remove vagi-
nal secretions, menstrual blood and post-coital discharge,
and was carried out within 2 hours of 45% of reported
sex acts [24]. A household survey among 3610 women in
Mozambique, South Africa, Indonesia and Thailand
found that the prevalence, type, frequency, and motiva-
tions for IVP varied significantly by setting, with intrava-
ginal cleansing and insertion of traditional products most
common in African study sites and oral ingestion of pro-
ducts considered to have vaginal effects most common in
Asia [29]. IVP have the potential to negate the protective
efficacy of vaginal microbicides for HIV prevention either
by creating an adverse intravaginal environment (e.g. by
altering intra-luminal pH) or by mechanical means (e.g.
microbicide gel is washed out immediately after sex)
[24]. They are also likely to impact on the acceptability
and preference of different microbicide products in dif-
ferent settings (e.g. gels may be preferred in settings
where vaginal ‘wetness’ is desirable and where women
enhance lubrication through IVP; intravaginal rings or
film formulations may be preferred in settings where
women are concerned about partner perceptions of ‘ex-
cessive’ vaginal lubrication and where they use IVP to in-
duce a ‘drier’ vagina prior to sex) [27,35,36].
Although overall HIV prevalence is below 1% in virtu-
ally all Asia-Pacific countries, the region is second only
to sub-Saharan Africa in terms of the number of people
living with HIV [37]. The HIV epidemic in Asia has
been largely concentrated in people who inject drugs,
sex workers and their clients and men who have sex
with men, but increases in heterosexually-acquired HIV
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including Bangladesh [38,39], China [40,41], Indonesia
[42-44] and Pakistan [45,46]. Of particular note has
been the increase in the proportion of women living
with HIV in the region from 19% in 2000 to 35% in
2008, with striking increases observed in China [40]
and India [47]. There are emerging, generalized hetero-
sexual HIV epidemics in PNG and in neighbouring
Tanah Papua Province in Indonesia, with estimates of
adult HIV prevalence in the range 1-2% in these set-
tings [48]. Other countries in the Pacific have to date
experienced modest HIV epidemics but very high preva-
lences of sexually transmitted infections (STIs) have
been reported both among FSWs and in community-
based surveys [48-53]. The HIV epidemic in PNG is
primarily linked to heterosexual transmission and shows
significant heterogeneity, with over half the reported
HIV diagnoses coming from three of its 22 provinces
[54], placing women in some locations and socio-
cultural contexts at considerably higher risk of HIV in-
fection than others [48,54-58]. Some models have fore-
cast that under certain scenarios, adult HIV prevalence
in PNG could reach 10% over the next 15 years
[59,60]. In Indonesia, Tanah Papua Province is experien-
cing a generalized HIV epidemic that has many parallels
with the epidemic in neighbouring PNG. HIV preva-
lence among men and women aged 15–49 years in
Tanah Papua was recently estimated at 2.4%, the highest
in Indonesia and approximately 15 times the national
average [61]. Among ethnic Papuans, HIV prevalence
was almost twice that of other residents (2.8%, 1.5%
respectively).
In these settings, new, female-initiated HIV prevention
agents are potentially very appealing to both women at
risk and to public authorities responsible for prevention.
Apart from some limited trials of earlier candidate
microbicides in two sites in Thailand [62-66] and India
[66-72], virtually all of the recent trials of microbicides
have been conducted in African countries. Asia-Pacific
countries have been considered to have HIV incidence
that is too low to justify efficacy trials, but high enough
in some areas for microbicides to play an important role
in prevention once they are proven safe and efficacious.
In this paper we report findings from the first study
conducted in a moderate-prevalence setting in the Pacific
region to investigate intravaginal practices and vaginal
microbicide acceptability, and discuss the implications of
our findings on future HIV prevention policy and research
priorities.
Methods
This study was conducted over a nine-month period in
2010–11. Fieldwork and data collection were carried
out from April – June 2010, followed by the interviewdata transcription, translation, coding and qualitative
data analysis.
The study was conducted at Nine-Mile Sexual Health
Clinic in Port Moresby, PNG (Figure 1), which is located
in a disadvantaged urban area and administered by a
non-governmental organization (HOPE Worldwide,
PNG) on behalf of the National Capital District Depart-
ment of Health. In addition to providing services to
women and men from the general community, the clinic
has an active community outreach and peer support
program developed in collaboration with Family Health
International (FHI) PNG that is designed to facilitate
service uptake by people at increased risk of HIV/STI
acquisition, particularly male and female sex workers
and men who have sex with men. Clinic staff provided
an overview of the study to potential participants as part
of routine health talks (tok save) given at the start of
each day to clients attending the clinic. Peer educators
provided similar information to potential study partici-
pants through their community outreach activities.
Those who expressed an interest in hearing more about
the study and potentially taking part were invited to par-
ticipate in preliminary group discussions at the clinic in
which they were provided with more detailed informa-
tion about the study by trained researchers and clinic
staff. Clients who expressed an interest in study partici-
pation were then invited to take part in an in-depth
interview (IDI), which took place at a location of their
choice following the completion of informed consent
procedures. This study location was selected because of
the high proportion of women and men at increased
HIV/STI acquisition risk who attend this clinic, includ-
ing FSWs and their clients, and vulnerable individuals
living in illegal urban settlement areas. Separate IDI
guides were developed for interviews with women and
men by the research team, in consultation with clinic
staff. IDI guides included four thematic areas of inquiry:
background information; sexual behaviour and sexual
health; intravaginal and menstrual practices; and female-
controlled methods of HIV protection. All interviews
were conducted by trained, experienced and gender-
appropriate interviewers in tok pisin (VF, HA).
Socio-demographic and sexual behavioural data, in-
cluding experience of male and female condom use,
were collected from all participants. To facilitate discus-
sion on intravaginal hygiene and menstrual practices
(IVP), women were invited to use copies of a hand-
drawn template to indicate how they wash/clean their
vulva and/or vagina, and to provide commonly-used,
locally-appropriate names for anatomical structures by
labelling the drawing. Templates were developed by the
research team in consultation with clinic staff and
piloted with volunteers from the clinic for appropriate-
ness and acceptability prior to use. Women were also
Figure 1 Nine-Mile Sexual Health Clinic, Port Moresby, PNG.
Figure 2 Products used to make ‘dummy’ microbicide gel and
applicator.
Vallely et al. BMC Research Notes 2012, 5:613 Page 4 of 14
http://www.biomedcentral.com/1756-0500/5/613asked to comment on practices they had heard other
women in the community were conducting and to indi-
cate these using the template. Men were asked whether
they were aware of their sexual partners conducting such
practices or if they had heard about other women in the
community conducting such practices, and to use the
template to indicate these. Participants indicated IVP
using marker pens, highlighter pens, biro and/or pencils
provided by the study team and if literate, were asked to
write the names of anatomical structures onto the sheet.
Where participants were unable to read or write, inter-
viewers wrote down participant’s comments / anatomical
names on the sheet on their behalf, using English and/or
tok pisin depending on the language used by individual
participants.
Men and women were shown male and female con-
doms, which interviewers’ opened and encouraged parti-
cipants to handle and comment on. Participants were
asked to reflect on their experiences of condom use; the
factors that had determined use in different contexts and
behavioural scenarios; their personal views of condom
acceptability; and their views about acceptability and use
among women and men in the wider community.
Interviewers introduced the concept of a vaginal
microbicide to participants and demonstrated a surro-
gate microbicide gel and applicator, prepared prior to
each interview by research staff using commercially
available vaginal applicators that were pre-filled with 2-
3mL KY JellyW (Figure 2 and 3). This volume was
selected based on earlier microbicide efficacy trials, in
particular the MDP301 trial [4]. Interviewers demon-
strated how such a product would be used in practice,
based on information provided to MDP301 trialparticipants [73]. Participants were invited to handle the
surrogate microbicide and to ask any questions they may
have regarding future use of such a product.
Interviewer: ‘Now I’d like to talk to you about new
methods of protection being developed. We hope that
women will be able to use these to protect themselves
against HIV and sexually transmitted infections in future.
These products are known as ‘vaginal microbicides’ and
will probably be available in the form of vaginal gels or
creams. We hope that an effective microbicide will become
available in the next 3–5 years. I have here an example of
what a vaginal microbicide gel might look like (Hold up
pre-loaded dummy applicator). In future, women could
insert a gel like this into the vagina, either daily or just be-
fore each sex act, to protect them against HIV and
Figure 3 Demonstrating microbicide surrogate to study
participants.
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plicator would be inserted into the vagina; different
positions she could use for insertion; gel volume and
consistency. Give her the applicator to handle. En-
courage her to ask questions about microbicides).
Interviewers then asked participants to reflect on their
views of personally using such a product in future, in the
context of their individual sexual lives and reported IVP
e.g. would they tell their husband / sexual partner(s) that
they were using such a product or might they in some
situations consider covert use? Similarly, they were asked
to reflect on how such a product would be perceived
and used by the wider community.
All interviews were digitally recorded, transcribed ver-
batim and where necessary translated from tok pisin (a
lingua franca of PNG) into English at the PNG Institute
of Medical Research (PNG IMR) in Goroka. All personal
identifiers were removed from the interview transcripts
and pseudonyms given to each participant. Following
data cleaning and initial review of interview transcripts,
a preliminary coding framework was developed by the
research team to capture data relevant to each key the-
matic area of inquiry (e.g. respondents views on the fre-
quency of IVP among women in their community were
coded ‘IVP-freq-comm’; individual motivators for IVP
were coded ‘IVP-mot-self ’). The research team then
hand-coded printed interview transcripts. The coding
framework was periodically reviewed as data coding pro-
ceeded and additional codes and/or sub-codes added in
an iterative data management process. Themes were
derived from the data during preliminary analysis of the
coded transcripts, which was led by senior members of
the research team (LF, AV), prior to critical review and
discussion with the wider group e.g. to seek alternative
themes and explanations arising from the data. A sum-
mary of key findings and their interpretation was then
drafted (AV, LF) and illustrative quotes selected from
individual interview transcripts in order to exemplify
specific issues and concepts that had emerged across
the dataset.Ethical approval was obtained from the Medical Re-
search Advisory Committee (MRAC) in PNG and from
the Human Research Ethics Committees of the University
of Queensland and the University of New South Wales in
Australia. All participants provided written informed con-
sent in either English or tok pisin. All participants were
advised that they could withdraw from the study at any
time without prejudice. The study was conducted in
accordance with the RATS guidelines on qualitative re-
search (http://www.biomedcentral.com/ifora/rats).
Results
Twenty-eight IDIs were conducted with women (n=16)
and men (n=12) from diverse socio-cultural backgrounds
(Table 1). The majority of participants (19/28) lived in
urban settlements at the time of the study. Two women
who self-identified as FSWs took part in this research.
Traditional customs and norms relating to women’ bodies
Traditional customs and norms surrounding women’s
bodies were described by both male and female partici-
pants. Such traditions were reported as common among
people from communities in the Highlands of PNG,
where menstruating women isolate themselves from
male family members, not touching or preparing food,
or having sexual intercourse, for fear that maternal
blood could ‘contaminate’ or weaken men. Male partici-
pants drew on traditional stories of men being weakened
in warfare and becoming sick if they ate food prepared
by, or had sex with, menstruating women. Several men
described providing support to their wives during their
monthly menses, in order to support customary prac-
tices, for example:
“I’m an old man and at this time now. In the past when
women have their menstruation like my wife, when
having her flow and she cooks, I will not eat the food she
cooked . . .the food will not taste good and we will vomit.
She will not walk in front of me or close to where food
will be prepared. She will stay on her own for until one
or two weeks later she can hold or serve food. She can
bring food from the garden but I will cook for the family.
That is our traditional behaviour”. John, male
“So when this thing [period] comes I use to tell my
wife, let me cook, and you rest for four or five days”.
Mego, male
Women talked about the importance of flow of men-
strual blood from the womb, and how flow could be
‘blocked’ by sexual intercourse during menstruation.
Female participants described learning cultural practices
from female family and village members. Some partici-
pants lamented the discontinuation of traditional customs,
Table 1 Socio-demographic characteristics of study
participants
Women (n=16) Men (n=12)
Age
Age range (mean) 16–42 y (25 y) 17-54 y (30 y)
Marital status
Single 4 2
Married 10 9
Divorced 2 1
Current residence
Port Moresby (settlement area) 12 7
Port Moresby (non-settlement) 3 5
Reside outside Port Moresby - -
Province of origin / family origin
Central 2 1
Gulf 1 1
Milne Bay - 1
Oro - 1
Eastern Highlands 2 2
East New Britain 1 -
East Sepik 1 -
Simbu 5 2
Southern Highlands 1 4
Western Highlands 3 -
Occupation
Unemployed 14 8
Skilled employed - 2 (1 clerk; 1 teacher)
Unskilled employed - 2 (security guards)
Commercial sex worker 2 -
Figure 4 Example IVP templates completed by female study
participants.
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number of participants described how they themselves did
not follow all traditional cultural practices, for example,
by engaging in sexual intercourse during menstruation.
“The women when we have our monthly flow, we must
not cook food and give to our family members
especially our husbands. That is a very important
thing. I will not cook food and give. I must not come
close to the kitchen or the chair where my husband sits.
I must stay outside and they will give me food. It’s a
very big taboo for us to have sex with our husbands
during that time . . .it’s a belief that when he goes to the
village he will not have money, food or all these things
[if sex during menstruation occurs]”. Pate, female
Intra-vaginal hygiene and menstrual practices (IVP)
A diverse range of IVP were reported by female partici-
pants using the pre-tested template (Figure 4). Many
anatomical structures were referred to using descriptive
terms and did not appear to have specific names in tokpisin (e.g. bean for clitoris; grass for pubic hair) and
there was no common term for vulva. Vagina was com-
monly referred to as rot blong pikinini [Lit: ‘baby’s road’]
by both men and women; but kan used only infrequently
e.g. among sex workers.
A typology or classification framework of IVP has re-
cently been proposed, based on research conducted as
part of a WHO Gender, Sexuality and Vaginal Practices
(GSVP) Study, within which the results of the current
study have been summarised (Table 2) [30].
The majority of women in PNG described washing the
vulva only with soap and water as part of their daily rou-
tine; in preparation for sex; and following sexual inter-
course. Several women described cleaning inside the vagina
using fingers and soap at these same times. Others reported
cleaning inside the vagina using a hose connected to a tap;
use of vaginal inserts (such as crushed garlic for improved
genital health or ‘virgin soap’ for intravaginal tightening);
customary ‘steaming’ practices associated with menstru-
ation; and the use of material fragments, cloth, newspaper,
baby nappies and sanitary towels to absorb menstrual
blood. Unprotected sex during menstruation appeared
common and was reported by both women and men.
Washing was undertaken for the purposes of hygiene,
to avoid ‘bad smell’, to remove ‘dirt’, to prevent ‘sickness’,
Table 2 Summary of intravaginal practices reported by women and men taking part in this study, using the
classification proposed in the WHO Gender, Sexuality and Vaginal Practices Study [29]1
WHO Classification of Intravaginal Practices IVP reported in this study Motivators for IVP reported in this study
External washing (cleaning vulva / external genitalia) • soap and water – to stop smell / remove dirt
– to prevent sickness in the womb
– to have children
– to please sexual partners
Intravaginal cleansing (internal cleansing
or washing of the vagina)
• ‘Klina’ laundry soap – for genital cleansing
• bath soap and water – to help remove excess fluids
– to please male sexual partners
– to maintain reproductive health
External application (rubbing or placing products
onto the vulva / external genitalia)
Not reported Not reported
Intravaginal insertion (pushing or placing
something inside the vagina)
• cotton, paper, tampons – to absorb menstrual blood
‘virgin soap’ – to tighten vaginal wall in order to
increase male partner pleasure
• ‘Klina’ laundry soap – to induce abortion
– to help release menstrual blood
– for cleansing the vagina
• crushed garlic – to help ensure a healthy womb
– to contract cervix after childbirth
Oral ingestion • bark / leaves of specific trees – to prevent pregnancy
• ‘Klina’ laundry soap – to induce abortion
Vaginal steaming or smoking (sitting above a source
of heat on which water and herbs or oils are placed
to create steam or smoke)
• Steaming (using boiled water infused
with herbs / garlic /bark / leaves)
– to facilitate flow of menstrual blood
and prevent blockages
• Smoking (using burnt coconut leaves) – to cleanse and tighten the vagina
Anatomical modification (“cutting and pulling” for
modifying the vulva; restoration of the hymen)
Vulva piercing – to increase sexual pleasure
(male / female)
1IVP and motivators reported by a representative sample of those interviewed, unless otherwise indicated.
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about vaginal hygiene from their mothers and grand-
mothers as part of traditional rites of passage. For those
living in urban localities, friends were the main source of
information. It was acknowledged that urban residents
had more access to water and hence washed more regu-
larly than rural residents. Most described cleaning as a
private matter not discussed with male partners, al-
though a few participants did discuss IVP with their
partners, with some male partners actively helping part-
ners to wash.
“No I soap my outside body and wash it. . . I don’t
push it right in [the vagina] but just enough to wash
it”. Seguto, female
“I don’t think all women do this because when I walk
past them, I smell their body odour. . .they don’t wash
it [vagina] properly. . .dirt is still there and it comes
down on the underwear and bad air comes from it
that causes the bad smell. . . Personally I fear of
getting sick inside the womb so the way I wash myself
is that, I open my two legs and I put my hand rightinside. I put my hand right inside and wash it. . .not
all the fingers but only one or two fingers. . .I put
inside and soap it. I soap it, wash and rinse it
properly. I open my legs like this and I wash it. I’m
scared of diseases. So I wipe it with a towel when
washing and clean it properly”. Napoga, female
“..when they pass you it will smell and you will say
‘she must not have washed. . .she is smelly’. . .they must
wash every morning and afternoon. It is good they
keep their bodies and vaginas clean to protect
themselves and to have children easily”. Mego, male
A number of intravaginal practices were associated
with menstruation. The choice of menstrual products
was associated with price, availability and cultural norms.
Sanitary products were described as expensive and diffi-
cult to access. It was uncommon for women to use in-
ternal menstrual products. Participants who practiced
traditional customs associated with menstruation dis-
cussed the importance of releasing menstrual blood and
did not use tampons or other internal products for fear
that these would ‘stop the flow’ of blood and cause sick-
ness. To aid the flow of blood, a few women described
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leaves, and ‘steaming’, which involved sitting over hot
water infused with herbs and garlic, or leaves from
lemon, guava and avocado trees.
“I think that when wearing modes [sanitary pads] or
toilet roll and all this, it blocks the bad air back inside
and by this I think it will cause sickness inside”.
Napoga, female
“Some women tear off pieces of cloth and put it into
their underwear or such. They can’t afford to buy
[sanitary products] so, they use newspapers. Okay
some women wear laplaps [cloth wrap-around skirt].
They just roll down or put it to their back. Women in
the village wear these laplaps to stop themselves
staining their trousers or skirts. Some women stay
inside the house”. Kakana, female
“I pour the water [herbal infusion] into a bucket, sit
down on the bucket and the steam will go inside. It
will clean the dirt inside and you will see it in the
water. After steaming, you will feel light and nice.
When we wear pads, it blocks the bad blood inside.
When you steam the blood will come outside . . .the
dish will be full of it’ Napoga, female
Several female respondents reported hearing of
women cutting up soap bars (e.g. ‘Klina’ soap available in
PNG) into small blocks and inserting them into the va-
gina prior to menstruation. When menstrual blood
appears, the soap is washed out.
Many female participants reported sex during menstru-
ation, often under pressure from their male partners, and
despite cultural taboos relating to these practices and to
the importance of menstrual exclusion among women
from Highlands communities. Women and men from
cultural groups that traditionally considered sex during
menstruation taboo reported engaging in such practices,
whilst recognising the conflict between their contempor-
ary and customary beliefs. Several male and female
respondents said they would not consider using a con-
dom when having sex during menstruation due to con-
cerns about the condom ‘blocking rubbish to come out’:
“And when I have my period, he asks to use a condom
but I use to say no. When he has sex with me during
my menstruation time, it stops, I don’t have my
period. He stops it and I get afraid of that because he
puts back inside; the rubbish. So I will get sick, it
worries me. Napoga, female
IVP for contraception and to induce abortion were
also described. Eating the bark and leaves of a certaintree was discussed as a form of contraception, or a
means to induce abortion e.g. in combination with the
intravaginal insertion of soap. Others described tying ‘a
rope around the belly, and putting soap inside the va-
gina’ to cause abortion.
“Yeah they usually mix hot water with soap and egg
and drink it. . . They drink it and it comes out like
blood”. Dorothy, female
‘Virgin soap’ was discussed by female participants as
an increasingly popular vaginal insert used by ‘mothers’
or ‘married’ women to tighten the vagina. The soap was
seen as a proactive method to keep male partners faith-
ful by making sexual intercourse more pleasurable for
them. One participant who had tried the soap described
a painful, burning experience:
“They said when we women give birth to children, our
muscles become weak but his soap will cause it to
tighten the women’s muscles. . . .I bought [virgin soap]
from one woman; they sold it for 5 Kina [approx. USD
2.00]. It was a small bit they sold and they said it was
virginity soap. They said if wash with this soap, it will
contract your muscles and you will become small and
16 again and when you have sex with your husband,
he will really like it. So they convinced me and I
bought one and used it only one time. I soaped myself
and they told me to put it into the vagina for around
30 or 20 seconds and it just burned me. It really
burned me and I just stopped and rinsed myself and I
said that I won’t use it again”. Kakana, female
In contrast to other settings [15,24,25], none of the
women interviewed reported inserting lemon, lime,
herbs or other substances (e.g. to increase or decrease
vaginal lubrication) and both women and men were un-
aware of such use in the wider community. The use of
vulval inserts was described by one female participant
(“they used to shave the hair of the vagina and put earr-
ings along the sides”), which she considered a practice
carried out mainly by women who engage in sex work.
Anecdotal accounts of such practices were also reported
by health care workers at Nine-Mile Clinic.
Female condom use and acceptability
The majority of men and women said they had not previ-
ously seen or handled a female condom but said they
would consider using one in future, primarily with non-
regular partners because they trusted their spouse or
long term partner. The dominant sexual practice dis-
cussed was ‘straight sex’or ‘skin to skin’, that is, vaginal
sex without a condom. Although some participants had
used male condoms, mainly for contraception, few did so
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against STIS/HIV. Condoms were described as being for
unmarried people, or those not in ‘trusting’ relationships.
“We think that condoms are for promiscuous people. . .
so we don’t think of using condoms: we do it skin to
skin”. Kakana, female
“We don’t usually use them [condoms]. He used to
talk about using it [a condom] but I usually say ‘I am
not your prostitute’ and ‘I have what kind of sick?’ and
I used to get cross with him; chase him away from the
house”. Napoga, female
When shown a female condom in the interview con-
text many participants were very interested in learning
about them, especially female participants, some of
whom were worried about their partner’s infidelity. Only
three women reported using a female condom in the
past, all of whom said that they would continue to use
and to negotiate use with their partners in future.
Vaginal microbicide gel acceptability
The majority of both women and men said that they
would use a product like the surrogate gel and applicator
to provide protection against genital infections, STIs and
HIV, should a safe and effective product become avail-
able in future. Many participants said that they would
use a future product because they thought it would not
only provide protection against STIs and HIV, but also
enhance the ‘health of the womb’ more broadly or ‘pre-
vent us getting sicknesses like other kinds of infection or
sexual disease or pregnancy’.
The majority of women and men interviewed in the
study thought that future microbicide use would be
most appropriate in perceived as ‘high-risk’ situations,
such as sex with non-regular, transactional or commer-
cial partners (‘two Kina meri’). Many respondents
thought it unnecessary to use a microbicide with
‘trusted’ partners, as the following quotes illustrate:
“The sex workers who go around having sex, these
kinds of women usually get the sick and give it to the
men, so it’s good that they bring this medicine now so
that it will help us, the married couple. These women
have sex with our husbands and they spoil our
married life. The married man will bring the sick, so
it’s more good that the medicine will come and the
women will use this, and the sick will not come into
the married couple. I want this medicine to come”.
Napoga, female
“I won’t tell her [my wife] to use it because she trusts
me and I trust her” Moko, male“I trust him [steady boyfriend]. . .I will use it only with
some other partners” Daisy, female
Most women felt confident that they would be able to
negotiate future vaginal microbicide use with their sexual
partners but if necessary, would be prepared to use pro-
ducts covertly. Covert use was considered empowering
for married women who were worried about their hus-
band’s infidelity. Some female participants however,
questioned covert use for fear of inciting male partner
anger or violence.
“I like what you said about using this gel. You know I
am a housewife and the man is working and he goes
out. Sometimes when I insist to use a condom
during sex he will say, ‘I’m not your boyfriend’ and he
will throw it away. I like what you talked about the
gel and my husband will not know about it if I use,
knowing that he’s having affairs outside”.
Pate, female
“It’s my secret so I will insert it [vaginal microbicide]
and we will have sex. I will not tell them because some
have diseases and are thinking to give it to me. If I put
this medicine in [with their knowledge] they will be
cross, get upset and hit me.’ Dorothy, female
When shown the surrogate microbicide most women
agreed that the product would be easy to use, and could
be applied in various geographical locations before sex.
Some women expressed concerns that applicators might
be difficult to use without initial counselling and support
from health care staff; that incorrect use could result in
vaginal trauma; that gel might leak out when urinating
or standing up; that gel use could affect a woman’s abil-
ity to conceive.
“If we don’t put it in properly it might go right
inside. . .might damage the vagina”. Dorothy, female
Many women asked questions regarding the ‘wetness’
that the gel would cause, and what the reaction of
male partners might be to this, especially if gel were
being used covertly. ‘Wetness’ was associated with
menstruation or having an STI, and some female parti-
cipants feared the reaction of male partners if extra
wetness were perceived. One female participant how-
ever described how increased vaginal lubrication might
make sex more pleasurable for women.
“Yeah when I insert this medicine inside and when we
want to have sex, he will ask me about the wetness. He
will ask me if I’m having my monthly menstruation”.
Dorothy, female
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woman’s vagina is dry and if this thing is put inside
and it becomes watery, the men will ask the women to
clean it and there’s no choice”. Seguto, female
“If our husbands don’t agree and we use this medicine,
we put it and they thinks it is too greasy and they find
out, this too will bring some problems into the family”.
Kakana, female
One female participant questioned the use of the
microbicide for fear that it would ‘block’ the flow of ma-
ternal blood, and cause sickness to the womb:
“. . .when we put this thing inside, it will block this
monthly flow to come outside and will cause some
kind of problem to the womb. It will go and damage
the tube inside where the flow comes”. Daisy, female
Male participants were generally positive about the po-
tential benefits of a vaginal microbicide for the health of
their female partners and for their own protection
against STIs/HIV, however two male participants sug-
gested that the use of a vaginal microbicide might cause
more ‘promiscuous’ sexual behaviours.
“I think that we must not put it in public; we must
give it to the people who come to the clinic only. If they
want to use it they must use it themselves . . .putting it
public will make them think that the medicine have
come already so they can do it [have sex] and when
they continue to do that it might increase the HIV rate
in PNG. I saw in the newspapers that the HIV rate of
Australia is 0.02% or something and PNG is 2% or 3%
and up. We have a small population and they
introduced condoms in public and this has made it
worse so how will this [microbicides] reduce this?”
Mego, male
Discussion
Intra-vaginal hygiene and menstrual practices (IVP) were
diverse in nature, socio-cultural dimensions and motiva-
tors in this setting. A dynamic combination of traditional
and contemporary practices were reported, with some
women engaging in new practices that they recognised
as being in conflict with traditional norms and
beliefs (e.g. the use of ‘virgin soap’; sex during menstru-
ation). Broad reproductive health concerns (maintaining
genital cleanliness, removal of ‘dirt’, preventing ‘bad
smell’, maintaining a ‘healthy womb’) appeared to be
more important motivators of vaginal practices than
specific concerns focussed on enhancing sexual pleasure
or on the prevention of HIV and STIs. The WHO Gen-
der, Sexuality and Vaginal Practices (GSVP) Studyincluded a household survey on IVP conducted among
3610 women aged 18–60 years in Mozambique, South
Africa, Indonesia and Thailand [29,30], and found that
the prevalence, motivators and contexts of vaginal prac-
tices varied markedly between countries. IVP in partici-
pating African sites appeared to be motivated primarily
by a desire to maintain male partner commitment and
to increase male and female sexual pleasure. Conversely,
in participating sites in Asia, genital hygiene and femin-
inity were primary motivators. Researchers in a variety
of settings [15,24,29,30,33,74] have similarly distin-
guished ‘sexual-related’ and ‘hygiene-related’ IVP, and
highlighted the potential of vaginal washing, insert and
other practices (conducted at different time points, and
driven by different motivators), to modulate susceptibil-
ity to HIV/STI acquisition and transmission. For ex-
ample, women who use lime or lemon juice
intravaginally (e.g. as a traditional contraceptive; for pro-
tection against genital infections; or for enhanced male
sexual pleasure [24,34,75]) are likely to be at increased
risk of cervical dysplasia, cervical epithelia disruption
and HIV acquisition, based on recent laboratory and
clinical trials data [76-80]. The use of soaps, deter-
gents, and other products used as part of daily genital
hygiene or carried out before and/or after sex, could
potentially result in vaginal irritation, inflammation or
epithelial disruption, thereby increasing infection risk.
A recent systematic review and meta-analysis of 15
studies in Africa and the USA concluded that intrava-
ginal practices do not appear to protect women from
STIs, genital infections or HIV, and that there is in-
conclusive evidence whether some practices may in-
crease acquisition risk [22].
Depending on their nature and timing, vaginal prac-
tices also have the potential to negate the protection
afforded by vaginal microbicides, either by mechanical
means (e.g. microbicide gel is diluted or washed out) or
through chemical interaction (e.g. vaginal insert chemically
reacts with microbicide product or alters intravaginal en-
vironment sufficiently to reduce product effectiveness).
Although we attempted to clarify the temporal relation-
ship between IVP and vaginal sex in this study, it was
not possible to establish precise estimates during in-
depth interviews with participants. Vaginal insert prac-
tices appeared uncommon in this setting and no respon-
dents reported the insertion of lemon or lime juice. Sex
during menses was however common and has the poten-
tial to increase the risk of HIV infection due to blood
exposure (particularly transmission to uninfected male
partners [81-85]), and to reduce microbicide effectiveness
due to altered vaginal pH and other physiological
changes [86-88]. Further research is warranted, using
combinations of behavioural research methods as utilised
in other settings [24,74,89-91], to better understand these
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microbicide uptake, adherence and effectiveness in PNG.
Notional acceptability of vaginal microbicide gels for
HIV/STI prevention was high among both women and
men in this study. Microbicide acceptability was per-
ceived within a broad reproductive health framework i.e.
that use would promote a ‘healthy womb’ or help ‘pre-
vent sickness or pregnancy’, in addition to preventing
HIV. This perception was held by women and men and
is in contrast to advice provided by the research team.
Conversely, one female respondent was concerned that
gel could ‘block’ menstrual flow and cause sickness in
the womb. Many women and men thought that microbi-
cides would best be used by sex workers and considered
use between ‘trusted partners’ unnecessary. Most women
were confident that they would be able to negotiate gel
use with their sexual partners in future and many were
prepared to use microbicides covertly should their part-
ner refuse. Other women were concerned that increased
vaginal ‘wetness’ would make truly covert use difficult
and could expose them to increased risk of physical or
sexual violence. There were mixed views on the potential
of microbicide gels to modify sexual pleasure for women
and their male partners. Some women reported that
their partners preferred ‘their vagina dry’ and that men
would ‘ask women to clean it [out]’ should they use gel;
one woman reported that increased vaginal lubrication
would make sex more pleasurable for women. Women
were confident that they could use a product similar to
the surrogate microbicide in future but some were con-
cerned that initial use might be problematic without ap-
propriate counseling and support from health workers.
These findings clearly have implications for future
microbicides research and for the introduction of safe
and effective vaginal microbicides for HIV prevention in
PNG.
Low levels of awareness and lack of experience using
female condoms are cause for concern, but also repre-
sent an important opportunity for comprehensive HIV
prevention programs in PNG, given that notional accept-
ability was high among women and men in this study.
Further research to clarify in-use acceptability and ad-
herence of female condoms, including gendered sexual
dynamics, socio-cultural contexts and motivators influ-
encing use, are warranted to inform female condom pro-
motion programs in this setting.
A challenge in countries such as PNG that have
great geographic, linguistic and cultural diversity is to
develop culturally-nuanced and innovative strategies
for HIV prevention. This study has shown that women
and men from a variety of socio-cultural backgrounds,
who are at increased risk of HIV/STI acquisition, are
notionally supportive of vaginal microbicides for HIV
prevention in this setting. The need to engage malepartners in microbicides research and in strategies for
future product introduction has been recognized
[13,27] and is essential in countries such as PNG
where sexual dynamics are particularly male domi-
nated. It remains unclear how other microbicide
formulations currently in development (such as intra-
vaginal rings, dispersible vaginal tablets and films [8-10])
would be perceived and most effectively incorporated into
people’s individual sexual lives in this setting. In-use ac-
ceptability research planned by our group will address
these issues in future.
What are the implications of our research findings for
HIV prevention in PNG and other Asia-Pacific coun-
tries? Firstly, our findings need to be interpreted with
caution given the modest sample size, purposively
selected from a population of women and men attending
an urban sexual health clinic in a disadvantaged area of
Port Moresby, making generalisability problematic. This
population is however considered representative of
people at increased risk of HIV and STI acquisition in
PNG, a key potential target group for the future intro-
duction of vaginal microbicides and other biomedical
prevention technologies. Other limitations are that the
notional acceptability of alternative vaginal microbicide
formulations and dosing regimens were not evaluated in
this study (including coitally-independent products such
as intravaginal rings); and because this research was con-
ducted prior to the successful CAPRISA 004 trial result
becoming available, gel acceptability was not evaluated
in the knowledge that a safe and effective vaginally-
administered product had been identified. Although
biomedical prevention technologies such as male cir-
cumcision and vaginal microbicides are expected to play
an important role in comprehensive HIV prevention
strategies in high-burden settings, their role in moderate
prevalence settings is less clear. A key challenge having
investigated notional acceptability and the determinants
of acceptability will be to decide how future interven-
tions could best be implemented in order to ensure the
greatest public health impact. Population-level imple-
mentation of a moderately-effective vaginal microbicide
is likely to be less cost-effective in lower burden settings
than targeted introduction among those most at-risk of
HIV acquisition [92-94], such as women in HIV sero-
discordant relationships or female sex workers [95]. The
ethical and moral hazards of not making such products
widely available to all women clearly also need to be
considered, particularly in countries where women’s sex-
ual agency may be very limited, but should be balanced
against potential risks such as condom migration [12,14]
and the emergence of antiretroviral drug resistance [96].
Comprehensive guidance on these issues for low and
moderate burden settings is not currently available but
is urgently required to guide HIV prevention policy
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[97,98] and epidemiological mathematical modeling
[92,93] being conducted by our group are assisting pol-
icy makers and development partners in PNG to develop
evidence-based policy. This approach may represent a
model for other moderate-burden countries considering
a combination of biomedical prevention technologies for
HIV prevention.
Conclusions
Notional acceptability of a vaginal microbicide gel for
HIV prevention was high among women and men at
increased risk of HIV and STI acquisition attending a
sexual health clinic in PNG. Further research is war-
ranted to investigate the in-use acceptability and adher-
ence of different microbicide formulations in this
setting, and to establish the role of vaginal microbicides
and other biomedical prevention technologies in coun-
tries experiencing moderate-burden HIV epidemics.
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